The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company, with partial American and British roots. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue.
Company profile
Ticker
TAK, TAK-MM
Exchange
Website
CEO
Christophe Weber
Employees
Location
Industry (SIC)
SEC CIK
TAK stock data
Latest filings (excl ownership)
SD
Conflict minerals disclosure
25 Apr 24
6-K
Current report (foreign)
19 Apr 24
6-K
Current report (foreign)
15 Apr 24
6-K
Current report (foreign)
27 Mar 24
6-K
Current report (foreign)
9 Feb 24
6-K
Current report (foreign)
2 Feb 24
6-K
Current report (foreign)
1 Feb 24
6-K
Current report (foreign)
1 Feb 24
6-K
Current report (foreign)
16 Jan 24
6-K
Current report (foreign)
14 Dec 23
Latest ownership filings
SC 13D/A
Phathom Pharmaceuticals, Inc.
10 Apr 24
SC 13D/A
Phathom Pharmaceuticals, Inc.
1 Apr 24
SC 13G/A
BlackRock Inc.
6 Feb 24
SC 13G/A
Sumitomo Mitsui Trust Holdings, Inc.
5 Feb 24
4
Phathom Pharmaceuticals, Inc.
25 Jan 24
SC 13D/A
Phathom Pharmaceuticals, Inc.
25 Jan 24
SC 13G
Equillium, Inc.
19 Jan 24
144
Notice of proposed sale of securities
10 Jul 23
144
Notice of proposed sale of securities
10 Jul 23
144
Notice of proposed sale of securities
10 Jul 23
Financial summary
Quarter (USD) | Mar 23 | Mar 22 | Mar 21 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Mar 23 | Mar 22 | Mar 21 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q4 2023
4.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 246 |
Opened positions | 41 |
Closed positions | 98 |
Increased positions | 50 |
Reduced positions | 99 |
13F shares | Current |
---|---|
Total value | 810.21 bn |
Total shares | 152.57 mm |
Total puts | 0.00 |
Total calls | 451.50 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
CMTDF Sumitomo Mitsui Trust | 87.40 mm | $0.00 |
Capital Research Global Investors | 14.30 mm | $204.03 bn |
Mondrian Investment Partners | 8.17 mm | $116.55 bn |
MS Morgan Stanley | 4.85 mm | $69.17 bn |
GS Goldman Sachs | 4.30 mm | $61.40 bn |
Renaissance Technologies | 3.33 mm | $47.48 mm |
Brandes Investment Partners | 2.65 mm | $37.83 bn |
MCQEF Macquarie | 2.45 mm | $34.90 bn |
FMR | 2.18 mm | $31.09 bn |
Arrowstreet Capital, Limited Partnership | 1.91 mm | $27.23 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
24 Jan 24 | Takeda Pharmaceutical | Common Stock | Sell | Dispose S | No | No | 8.1 | 3,703,703 | 30.00 mm | 3,755,583 |
17 Apr 23 | Takeda Pharmaceutical | Series A Convertible Preferred Stock Common Stock | Other | Dispose J | Yes | No | 40.08 | 1,000,000 | 40.08 mm | 0 |
30 Nov 22 | Takeda Pharmaceutical | Common Stock | Acquire X | Yes | No | 0 | 5,883,500 | 0.00 | 6,724,000 | |
30 Nov 22 | Takeda Pharmaceutical | Warrant Common Stock | Dispose X | Yes | No | 0.0001 | 5,883,500 | 588.35 | 0 |
News
HUTCHMED Announces Positive CHMP Opinion For Fruquintinib In Previously Treated Metastatic Colorectal Cancer Received By Takeda
26 Apr 24
Takeda Receives Positive CHMP Opinion For Fruquintinib In Previously Treated Metastatic Colorectal Cancer
26 Apr 24
Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder
23 Apr 24
Reported Earlier, Takeda Announces U.S. FDA Approval Of ENTYVIO Subcutaneous Administration For Maintenance Therapy In Moderately To Severely Active Crohn's Disease
19 Apr 24
Takeda Announces Approval Of ADZYNMA Intravenous Injection 1500 In Japan For Patients With Congenital Thrombotic Thrombocytopenic Purpura
26 Mar 24
Press releases
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
26 Apr 24
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
22 Apr 24
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease
18 Apr 24
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
27 Mar 24
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
26 Mar 24